133
Participants
Start Date
December 27, 2023
Primary Completion Date
January 13, 2025
Study Completion Date
January 31, 2025
DMB-I (Dimebon)
20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
Placebo
20 mg 3 times a day, or 10 mg + 10 mg 3 times a day (for DMB-I + Placebo arm)
"Federal State Budgetary Institution Federal center for brain and neurotechnologies of the Federal Medical and Biological Agency (FSBI FCBN of Russia's FMBA)", Moscow
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow
"Centre of evidence-based medicine LLC", Yaroslavl
State public healthcare institution Leningrad regional psychoneurologic dispensary, Roshchino
"Saint Petersburg State budgetary healthcare institution City Hospital № 40 of Kurortniy district", Saint Petersburg
"Medical Center Nova Vita", Rostov-on-Don
"State autonomous healthcare institution Transregional Clinical Diagnostic Center", Kazan'
Lead Sponsor
Bigespas LTD
INDUSTRY